Neurocrine Biosciences | NBIX - Operating Profit



Neurocrine Biosciences reported $145.6M in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
AbbVie USD 5.72B 1.98B Jun/2025
Acadia Pharmaceuticals USD 32.37M 13.08M Jun/2025
Agios Pharmaceuticals USD -127056000 20.43M Jun/2025
ALKERMES USD 92.98M 79.19M Jun/2025
Alnylam Pharmaceuticals USD -16199000 34.28M Jun/2025
Amgen USD 2.66B 1.37B Jun/2025
Biogen USD 851.8M 540.6M Jun/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Cytokinetics USD -111506000 44.12M Jun/2025
Dynavax Technologies USD 10.86M 34.49M Jun/2025
Exelixis USD 215.68M 28.82M Jul/2025
Gilead Sciences USD 2.7B 467M Jun/2025
Halozyme Therapeutics USD 202.44M 60.91M Jun/2025
Incyte USD 310.82M 105.66M Jun/2025
Ionis Pharmaceuticals USD 139.84M 285.84M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
Pfizer USD 2.6B 1.06B Jun/2025
Prothena USD -52010000 12.89M Jun/2025
Regeneron Pharmaceuticals USD 1.08B 487.8M Jun/2025
Repligen USD 5.96M 621K Jun/2025
Sarepta Therapeutics USD 115.58M 415.96M Jun/2025
Teva Pharmaceutical Industries USD 899M 380M Jun/2025
Ultragenyx Pharmaceutical USD -193567000 50.63M Jun/2025
Vertex Pharmaceuticals USD 1.15B 123.1M Jun/2025